<DOC>
	<DOCNO>NCT03084861</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , two-arms phase I/II , clinical trial , 42 patient enrol principal objective evaluate efficacy change lesion size , secondary , evaluate safety efficacy corneal sensibility , corneal opacity , visual acuity complication Neurotrophic Keratopathy ( NK ) . Patients randomize 1:1 receive experimental treatment ( cord blood eye drop ) conventional treatment ( artificial tear therapeutic contact lens ) .</brief_summary>
	<brief_title>A Clinical Trial Asses Efficacy Safety Cord Blood Eye Drops Neurotrophic Keratopathy</brief_title>
	<detailed_description>This multicenter , randomize , open-label , two-arms phase I/II , clinical trial , 42 patient enrol principal objective evaluate efficacy change lesion size , secondary , evaluate safety efficacy corneal sensibility , corneal opacity , visual acuity complication NK . Patients randomize 1:1 receive experimental treatment ( cord blood eye drop ) conventional treatment ( artificial tear therapeutic contact lens ) . All patient , conventional experimental treatment , treat 19 day . A topical antibiotic add concomitant treatment treatment group , injury close accord medical criterion . After sign informed consent , inclusion exclusion criterion assess , patient meet requirement , patient randomize . After initiation treatment , patient follow-up 2-3 day week 3 week . A final follow-up plan 6 week .</detailed_description>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Age ≥ 18 year old 2 . NK stage 2 3 ( Mackie classification ) 3 . Signed Informed Consent Form 4 . The patient able understand nature study participate throughout duration 1 . Medical history eye tumor 2 . Active eye infection 3 . Eyelid bad position eyelid closure problem 4 . Conjunctiva scar 5 . Topic chronic eye treatment corticoids 6 . Acute corneal burn ( &lt; 3 month ) 7 . Intolerance contact lens 8 . Allergy inability receive concomitant treatment Exocin® 9 . Patients immunosuppressive chemotherapy treatment 10 . Pregnant woman woman without proper contraceptive method accord investigator ( * ) , lactate woman 11 . Participation another clinical trial last month ( * ) Contraceptive method accept protocol : hormonal , intrauterine device ( IUD ) , barrier method , voluntary sterilization patient menopause &gt; 1 year duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>